MENU
+Compare
KZIA
Stock ticker: NASDAQ
AS OF
Apr 17, 04:59 PM (EDT)
Price
$3.30
Change
-$0.24 (-6.78%)
Capitalization
3.69M

KZIA Kazia Therapeutics Limited Forecast, Technical & Fundamental Analysis

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs... Show more

Industry: #Biotechnology
KZIA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for KZIA with price predictions
Apr 16, 2025

KZIA sees its Stochastic Oscillator climbs out of oversold territory

On April 11, 2025, the Stochastic Oscillator for KZIA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for KZIA just turned positive on April 08, 2025. Looking at past instances where KZIA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KZIA advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .

KZIA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KZIA as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KZIA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KZIA entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.474) is normal, around the industry mean (13.668). P/E Ratio (0.000) is within average values for comparable stocks, (63.094). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (1.190) is also within normal values, averaging (249.208).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KZIA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KZIA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
KZIA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a company, which engages in the business of pharmaceutical research and development

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
300 Barangaroo Avenue
Phone
+61 294724101
Employees
16
Web
https://www.kaziatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGRFX98.04N/A
N/A
AB Growth A
SPMCX6.81N/A
N/A
Saratoga Mid Capitalization C
LGOPX20.58N/A
N/A
Lord Abbett Growth Opportunities P
OEGNX20.99N/A
N/A
Invesco Discovery Mid Cap Growth R
SPRAX21.99N/A
N/A
PGIM Quant Solutions Mid-Cap Val A

KZIA and Stocks

Correlation & Price change

A.I.dvisor tells us that KZIA and CLNN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KZIA and CLNN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KZIA
1D Price
Change %
KZIA100%
-2.37%
CLNN - KZIA
33%
Poorly correlated
-1.63%
SPRY - KZIA
29%
Poorly correlated
-0.73%
RVMD - KZIA
29%
Poorly correlated
-0.33%
AVCTF - KZIA
26%
Poorly correlated
N/A
IMAB - KZIA
26%
Poorly correlated
-7.26%
More